StreetInsider.com News Articles

Form 10-Q FILANA THERAPEUTICS, For: Jun 30

Wed, 29 Jul 2026 08:28:00 -0400

si-local-file:///var/storage/secattach/20260729/26831125.html

Form 10-Q FILANA THERAPEUTICS, For: Jun 30

Wed, 29 Jul 2026 08:28:00 -0400

si-local-file:///var/storage/secattach/20260729/26831125.html

Form 10-Q FILANA THERAPEUTICS, For: Jun 30

Wed, 29 Jul 2026 08:28:00 -0400

si-local-file:///var/storage/secattach/20260729/26831125.html

Form 8-K FILANA THERAPEUTICS, For: Jul 29

Wed, 29 Jul 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26831067.html

Form 8-K FILANA THERAPEUTICS, For: Jul 29

Wed, 29 Jul 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26831067.html

Form 8-K FILANA THERAPEUTICS, For: Jul 29

Wed, 29 Jul 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26831067.html

Filana Therapeutics, Inc. (FLNA) Tops Q2 EPS by 3c

Wed, 29 Jul 2026 08:09:38 -0400

Filana Therapeutics, Inc. (NASDAQ: FLNA) reported Q2 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Filana Therapeutics, Inc. (FLNA) click here.

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

Wed, 29 Jul 2026 08:00:00 -0400

AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.

“The Company continues to engage with the FDA regarding the clinical hold on its proof-of-concept trial in TSC-related epilepsy. The Company is working diligently to address the FDA’s request for information in order to have the clinical hold lifted,” said Rick Barry, President and Chief Executive Officer of Filana Therapeutics,

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

Wed, 29 Jul 2026 08:00:00 -0400

Form 8-K FILANA THERAPEUTICS, For: Jun 11

Mon, 15 Jun 2026 06:24:00 -0400

si-local-file:///var/storage/secattach/20260615/26643859.html

Form 8-K FILANA THERAPEUTICS, For: Jun 11

Mon, 15 Jun 2026 06:24:00 -0400

si-local-file:///var/storage/secattach/20260615/26643859.html

Form 8-K FILANA THERAPEUTICS, For: Jun 11

Mon, 15 Jun 2026 06:24:00 -0400

si-local-file:///var/storage/secattach/20260615/26643859.html

Maxim Group Starts Filana Therapeutics (FLNA) at Buy

Tue, 26 May 2026 07:50:44 -0400

Maxim Group analyst Jason M initiates coverage on Filana Therapeutics (NASDAQ: FLNA) with a Buy rating and a price target of $5.00.

For an analyst ratings summary and ratings history on Filana Therapeutics click here. For more ratings news on Filana Therapeutics click here.

Shares of Filana Therapeutics closed at $1.31 yesterday.

Maxim Group Starts Filana Therapeutics (FLNA) at Buy

Tue, 26 May 2026 07:50:44 -0400

Maxim Group analyst Jason M initiates coverage on Filana Therapeutics (NASDAQ: FLNA) with a Buy rating and a price target of $5.00.

For an analyst ratings summary and ratings history on Filana Therapeutics click here. For more ratings news on Filana Therapeutics click here.

Shares of Filana Therapeutics closed at $1.31 yesterday.

Form 10-Q FILANA THERAPEUTICS, For: Mar 31

Thu, 07 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26455237.html

Form 10-Q FILANA THERAPEUTICS, For: Mar 31

Thu, 07 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26455237.html

Form 10-Q FILANA THERAPEUTICS, For: Mar 31

Thu, 07 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26455237.html

Form 8-K FILANA THERAPEUTICS, For: May 07

Thu, 07 May 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26448955.html

Form 8-K FILANA THERAPEUTICS, For: May 07

Thu, 07 May 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26448955.html

Form 8-K FILANA THERAPEUTICS, For: May 07

Thu, 07 May 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26448955.html

Filana Therapeutics, Inc. (FLNA) Tops Q1 EPS by 10c

Thu, 07 May 2026 08:04:50 -0400

Filana Therapeutics, Inc. (NASDAQ: FLNA) reported Q1 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Filana Therapeutics, Inc. (FLNA) click here.

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Thu, 07 May 2026 08:00:00 -0400

AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the first quarter ended March 31, 2026 and provided a business update on the development of simufilam, an oral small molecule intended to modulate filamin A protein.

“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Thu, 07 May 2026 08:00:00 -0400

“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Thu, 07 May 2026 08:00:00 -0400

“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Thu, 07 May 2026 08:00:00 -0400

“2026 has been a year of important progress and new beginnings for Filana Therapeutics. Our new name reflects who we are—a team dedicated to rigorous science and to bringing new treatment options